Catheter Precision (NYSE: VTAK), Inc., a U.S.-based medical device company specializing in advanced products for the cardiac electrophysiology market, has received final approval to market its LockeT product in the United Kingdom. The regulatory green light completes the necessary steps for UK commercialization following the company’s CE Mark approval in May 2025.
LockeT, an FDA registered, Class I suture retention device used in wound closure after venous punctures, is now officially registered for sale in one of Europe’s most significant healthcare markets. The move signals a continued expansion of Catheter Precision’s international strategy, targeting increased adoption of its technologies across both established and emerging clinical settings. Last week, the company announced the successful completion of the first LockeT procedures in Germany. The milestone took place at Zentralklinik Bad Berka, one of Thuringia’s largest hospitals, known for its 20 clinics and specialist departments.
The company has also partnered with UK-based distributor HC21 to bring LockeT to market. The two companies have previously collaborated on other product lines. HC21, which generates approximately €180 million in annual revenue and employs over 500 people across the UK and Ireland, will leverage its extensive network and market access to support the product’s rollout.
LockeT is designed to improve post-procedure recovery by streamlining wound closure and reducing the need for extended hospital stays, potentially accelerating throughput in healthcare systems like the National Health Service in the United Kingdom.
Fatih Ayoglu, Sales Manager for EMEA & APAC, stated “We are proud to announce the approval of LockeT for use in the United Kingdom, marking a significant milestone in our mission to support healthcare systems with innovative, patient-centric solutions. LockeT’s intuitive design and ease of deployment not only enhance patient comfort and recovery but also enable earlier discharge following cardiac procedures. This directly supports NHS efforts to reduce waiting lists by freeing up hospital capacity and accelerating patient throughput. With the NHS recently achieving its first reduction in waiting lists in 17 years, LockeT is poised to contribute meaningfully to this momentum by helping clinicians deliver more treatments, more efficiently. We look forward to working closely with UK healthcare providers to bring LockeT’s benefits to patients nationwide.”
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
This article contains sponsored content. Please see our disclaimer at: https://prismmarketview.com/disclaimer/
The post Catheter Precision Expands European Footprint with Key Regulatory Win, LockeT Launch Cleared in the UK, Shares Up 32% appeared first on PRISM MarketView.